Summary
As many as 1 in 5 patients may not lose significant weight with GLP-1 drugs like Wegovy and Ozempic, despite their popularity and effectiveness in clinical trials.
Experts attribute this variability to genetic, hormonal, and brain-based differences in regulating energy, as well as factors like sleep apnea or medications that hinder weight loss.
Non-responders often face frustration, but doctors stress alternative options, including different medications, lifestyle adjustments, or older treatments.
“As many as” 20% so, less than 20%? So it’s more than 80% effective?
The article is about that 20% and how they’re feeling pretty shitty after taking a drug that works for 80% and not seeing weightloss despite the significant hype. It’s basically obesity experts trying to calm expectations slightly—the drug works for a lot of people but you can’t count on it being a magic bullet for everyone.
hahah yeah what an ass-backwards way of attempting shit on efficacy
To be honest, 80% effectiveness for a generation 2 of a long term drug is a pretty nice value, especially in this field and the regulatory mechanisms it affects.
That’s better than basically most psychiatric, antivirals, antihypertensive and antidiabetic medication.
Only a few long term drugs like contraceptives, some chemotherapeutics and some hormone replacement drugs work that well in that many cases. And most of them are not Gen 2 drugs in a new field.
What, you’re saying weight is complicated and not just down to one factor for everyone?!
It’s cool we have proof of this via the magic drugs.
I wonder if they will respond better to retatrutide, since it’s a glucagon triple agonist.
